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Background: Tetrahydrobiopterin is an essential cofactor for the hydroxylation of aromatic amino acids
phenylalanine, tyrosine, and tryptophan. Therefore, tetrahydrobiopterin deﬁciency results in hyper-
phenylalaninemia as well as dopamine and serotonin depletion in the central nervous system. The enzyme
6-pyruvoyltetrahydropterin synthase catalyzes the second step of de novo synthesis of tetrahydrobiopterin,
and its deﬁciency is the most frequent cause of tetrahydrobiopterin metabolism disorders.
Method: We conducted a retrospective chart review of 28 subjects from 24 families with molecularly
conﬁrmed 6-pyruvoyltetrahydropterin synthase deﬁciency from six centers in three Arab countries. We
reviewed clinical, biochemical, and molecular data. We also reviewed previously published cohorts of
subjects with 6-pyruvoyltetrahydropterin synthase deﬁciency.
Results: Similar to previous observations, we show that early treatment (less than two months) is asso-
ciated with better outcome. We identify eight PTS variants in 24 independent families. The most common
variant is (c.238A>G; p.M80V) with an allele count of 33%. We also identify one novel variant (c.2T>G; p.?).
Conclusion: The deﬁciency of 6-pyruvoyltetrahydropterin synthase is relatively common in the Arab
population and should be considered in individuals with hyperphenylalaninemia. More natural history
studies with comprehensive biochemical and molecular genetics data are needed for a robust base for
the development of future therapy.
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Introduction
Phenylketonuria (PKU; OMIM #261600), which was ﬁrst re-
ported by Asbj€orn F€olling in 1934, is one of the most common
inborn errors of metabolism with an estimated prevalence of 1 in
10,000 in the European population1. PKU was the ﬁrst disorder for
which newborn screening was established through bacterial inhi-
bition assay by Robert Guthrie and Ada Susi in 1963.2 PKU is caused
by the deﬁciency of phenylalanine hydroxylase, which catalyzes the
hydroxylation of phenylalanine to generate tyrosine (Fig). As a
result, phenylalanine will accumulate to toxic levels causing irre-
versible intellectual disability (ID).
Hydroxylation of phenylalanine to tyrosine through phenylala-
nine hydroxylase requires the essential cofactor tetrahy-
drobiopterin (BH4) that was ﬁrst identiﬁed in the 1960s.3 More
than a decade later, a subgroup of individuals with PKU who
developed progressive neurological deterioration despite early di-
etary management was identiﬁed.4 The term malignant hyper-
phenylalaninemia was then used to describe subjects who were
found to have deﬁciency in BH4, the cofactor for phenylalanine
hydroxylase.5
BH4 is synthesized de novo from guanosine-50-triphosphate (GTP)
through a sequence of three reactions carried out by guanosine-50-
triphosphate cyclohydrolase I, 6-pyruvoyltetrahydropterin synthase
(PTPS), and sepiapterin reductase. During hydroxylation of aromatic
amino acids, BH4 is oxidized to pterin-4a-carbinolamine. BH4 is then
recycled through the action of two enzymes, pterin-4a-carbinolamine
dehydratase and dihydropteridine reductase6 (Fig). Defects in any of
these enzymes will result in BH4 deﬁciency. Sepiapterin reductase
deﬁciency and autosomal dominant form of guanosine-50-triphos-
phate cyclohydrolase I deﬁciency present, however, without hyper-
phenylalaninemia (HPA).7
In addition to its role in phenylalanine hydroxylation, BH4 is also
an essential cofactor for tyrosine and tryptophan hydroxylases,
which are rate-limiting enzymes in catecholamine and serotonin
biosyntheses, respectively. Therefore, besides HPA, BH4 deﬁciency
also results in dopamine and serotonin depletion in the central
nervous system.8 This accounts for the progressive neurological
deterioration in that subset of individuals with HPA despite early
dietary management. Finally, BH4 is also an essential cofactor for
the three isoforms of nitric oxide synthase.
Disorders of BH4 metabolism account for only 1% to 2% of pa-
tients with HPA in Europeans,8 whereas they are more common in
some other ethnic groups. For example, BH4 deﬁciency accounts for
more than 10% of HPA patients in some countries in East Asia9,10
reaching up to one-third of cases in some reports.11 In a cross-
sectional study from Iran, 76 of 617 (12%) with HPA have BH4 de-
ﬁciencies.12 In one old report from south Brazil, PTPS deﬁciency
alone represents 17% of cases with HPA.13
Methods
We reviewed the electronic and paper medical records of 28
subjects with molecularly conﬁrmed PTPS deﬁciency from four
centers in Saudi Arabia, one center in Oman, and one center in
Qatar. We used a case report form to collect the demographic
characteristics of the subjects, the age and pattern of the initial
presentation, the clinical phenotype, and the biochemical, radio-
logical, and molecular features. Literature review was conducted
using PubMeb search (https://www.ncbi.nlm.nih.gov/pubmed/).
The nomenclature of variants is according to the Human Genome
Variation Society recommendations. This study was approved by
King Fahad Medical City Institutional Review Board (Institutional
Review Board registration number H-01-R012).
FIGURE. Biosynthesis of BH4 and consequences of defect in PTPS. AADC, aromatic L-amino acid decarboxylase; DHPR, dihydropteridine reductase; GTPCH, GTP cyclohydrolase I; 5-
HIAA, 5-hydroxyindoleacetic acid; HVA, homovanillic acid; NOS, nitric oxide (NO) synthase; PCD, pterin-4a-carbinolamine dehydratase; PAH, phenylalanine hydroxylase; PTPS, 6-
pyruvoyltetrahydropterin synthase; SR, sepiapterin reductase; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase.
M. Almannai et al. / Pediatric Neurology 96 (2019) 40e47 41
Results and discussion
Local experience: report of 28 Arab subjects
A total of 28 individuals with PTPS deﬁciency have been iden-
tiﬁed and included in this study. All are Arabs, but they belong to
different geographical regions including Saudi Arabia (n ¼ 21),
Oman (n ¼ 5), Egypt (n ¼ 1), and Sudan (n ¼ 1). There is an equal
distribution of males and females (46%:54%). Most individuals in
our cohort were born to consanguineous parents (89%). Prematu-
rity was evident in 15% of the subjects, whereas 40% were born
small for gestational age. The birth weight range was 1.25 to 3.0 kg
(mean 2.3, median 2.25). Microcephaly was evident in 10 of 20
subjects (50 %).
Ten subjects were diagnosed by newborn screening (NBS), 17
were symptomatic, and the remaining one was diagnosed early
because of family history. Some of those who were diagnosed by
NBS were already symptomatic in the neonatal period
(Supplementary Table 1). The age range of diagnosis for those
diagnosed symptomatically was neonatal period to 9 months
(mean 2.6 months, median 1.5 months). Among subjects who
presented with early symptoms, common presenting complaints
include hypotonia (11 of 20: 55%), seizures (ﬁve of 20: 25%), and
lethargy and irritability (four of 20: 20%). The age range of initiation
of treatment for those diagnosed with NBS was two days to two
months (mean 27 days, median 22 days), and for the rest of sub-
jects, it was one month to three years (mean 11.5 months, median
10 months).
In regard to the biochemical proﬁle on presentation, phenylal-
anine levels ranged between 201 and 2665 mmol/L (mean 1111,
median 1039) in subjects diagnosed by NBS, and it was comparable
to those of subjects diagnosed symptomatically, 360 to 2373 mmol/L
(mean 1128, median 1037 [P ¼ 0.95]). Pterin analysis on presenta-
tion is available for eight subjects (seven urine samples and one dry
blood spot). All but one subject (subject #20) had high neopterin
(range 3.9 to 29.3 mmol/mol Crea, mean 13.2, median 13.4; refer-
ence range 1.1 to 4), whereas biopterin and biopterin/total pterins
ratio were low in all of them (Supplementary Table 1). In three
additional subjects, only the ratio is available, and it was low in all.
Only two subjects (subjects #11 and #21) had cerebrospinal ﬂuid
(CSF) studies available on presentation, and they showed typical
pattern with high neopterin, low biopterin, low 5-
hydroxyindoleacetic acid (5-HIAA), and low homovanillic acid
(HVA). Plasma prolactin is available for 17 individuals on presen-
tation (range 368 to 2890 mIU/L; mean 876, median 736).
The age range for individuals in this cohort at their last follow-
up visit was ﬁve months to 18 years (mean 5.1 years, median
4.4 years). Phenylalanine levels on last follow-up ranged between
26 and 1677 mmol/L (mean 156, median 62) (note: the subject who
had a value of 1677 was known to be noncompliant). Follow-up CSF
studies on last follow-up are available for only two subjects (sub-
jects #2 and #4, Supplementary Table 1). Plasma prolactin levels on
last follow-up ranged between 25 and 10,788 (mean 1461, median
476).
In regard to treatment, all subjects but one (subject #20, non-
compliant) are on BH4 (dose range 3.2 to 21 mg/kg/day, mean 11,
median 10) and L-dopa (dose range 2 to 15 mg/kg/day (mean 7.7,
median 6.3), 19 of 27 are taking 5-hydroxytryptophan (5-OH-Trp)
(dose range 1.6 to 10 mg/kg/day; mean 5.5, median 6), and seven
subjects are on folinic acid.
Most of our subjects (23 of 27; 85%) show variable degrees of
developmental delay or ID. All subjects who were treated late
(greater than two months) (n ¼ 13; outcome not available in sub-
ject #28) have global developmental delay or ID, only one of them
had an intelligence quotient (IQ) testing performed, and it was 50.
On the other hand, the outcome is better in subjects who were
treated early ( 2 months) (n ¼ 14). Four of them have normal
development, and ﬁve more have mild delays only. The remaining
ﬁve subjects have global developmental delay; two of them have
had IQ testing performed, and it was in the mild ID range (59 and
62). Peripheral hypertonia is commonly observed in our cohort (15
of 25; 60%), whereas truncal hypotonia is evident in half of the
subjects. Seizures are observed in 13 subjects (46%). Nine subjects
(33%) have movement disorders. Failure to thrive is observed in 14
subjects (52%), whereas 50% of them havemicrocephaly. Additional
clinical characteristics are summarized in Table 1.
Neuroimaging is available for nine subjects only, and it is normal
in ﬁve of them (obtained once, not repeated). Findings in the other
four subjects include abnormal T2 hyperintensities within the
posterior tegmental structures of the pons (subject #6, obtained at
age two months), mild white matter volume loss along bilateral
centrum semiovale (subject #12, obtained at six years), and white
matter changes with mild cerebral atrophic changes (subjects #22
and #27).
Eight pathogenic variants have been identiﬁed in this report for
24 independent families (Table 2); all were in homozygous status.
The most common variant is c.238A>G; p.M80V with an allele
count of 33%, followed by themissense variant (c.342C>G; p.I114M)
and the in-frame deletion (c.169_171del; p.V57del), both with an
allele count of 17%. These variants were identiﬁed in subjects from
Saudi Arabia only. One novel variant (subject #6) is identiﬁed in this
report; (c.2T>G; p.?)
TABLE 1.
Patient Cohort Characteristics
Variable Value
Number of subjects 28
Male: female (%) 46:54
Consanguinity 25 /28 (89%)
Ascertainment Family history: 1 (3%)
Positive newborn screening: 10 (36%)*
Symptomatic: 17 (61%)
Age at presentation in subjects
diagnosed symptomatically
(n ¼ 17)
Neonatal period-9 mo
(mean 2.6 mo, median 1.5 mo)
Presenting complaints Hypotonia (11/20, 55%), seizures (5/20;
25%), lethargy and decreased activity
(4/20; 20%), irritability (4/20; 20%),
oculogyric crisis (3/20; 15%),
developmental delay (3/20; 15%)
Initial phenylalanine level
(mmol/L) (n ¼ 24)
201-2665
(mean 1120, median 1037)
Age at start of treatment Diagnosed by NBS: 2 d-2 mo
(mean 27 d, median 22 d)
Diagnosed symptomatically: 1 mo-3 yr
(mean 11.5 mo, median 10 mo)
Age at last follow-up 5 mo-18 yr
(mean 5.1 yr, median 4.4 yr)
Most recent phenylalanine
level (mmol/L)
26-1677
(mean 156, median 62)
Most recent prolactin
level (mIU/L)
368-2890
(mean 876, median 736)
Treatment
BH4 (mg/kg/day) (n ¼ 27) 3.2-2.0 (mean 11 and median 10)
L-Dopa (mg/kg/day (n ¼ 27) 2.0 -15.0 (mean 7.7, median 6.3)
5-OH-Trp (mg/kg/day) (n ¼ 19) 1.6 -10.0 (mean 5.5, median 6)
Last clinical evaluation
Global developmental delay or ID 18/27 (67%)
Mid developmental delay 5/27 (18%)
Normal development 4/27 (15%)
Truncal hypotonia 14/28 (50%)
Seizures 13/28 (46%)
Movement disorders 9/27 (33%)
Microcephaly 12/24 (50%)
* 3 subjects with abnormal NBS had early symptoms before diagnosis was made;
see Supplementary Table 1.
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PTPS deﬁciency is the most frequent BH4 metabolism disorder
Of the BH4 metabolism disorders, PTPS deﬁciency accounts for
more than 60% of cases.14 As of February 13, 2017, there are 1118
subjects in the International Database of Tetrahydrobiopterin De-
ﬁciencies (BIODEF), 735 (66%) of whom have PTPS deﬁciency
(http://www.biopku.org/biodef/BIODEF_Start.asp).
PTPS deﬁciency is a pan-ethnic disorder. Chinese subjects
represent 51% (372 of 735) of subjects listed in the BIODEF database,
whereas Caucasians and Arabs represent 12% (86 of 735) and 8% (57
of 735), respectively. On the other hand, PTPS deﬁciency is un-
common in Africans and Hispanics. None of the subjects listed in
the BIODEF database are of Jewish ancestry.
There are two recognized forms of PTPS deﬁciency. The mild or
peripheral form is characterized by normal levels of CSF neuro-
transmitters in the initial stages, and a good response to BH4
monotherapy.8 The other form, which is the severe, or the typical,
form presents early and is characterized by developmental delay/
ID, convulsions, and abnormal tone and movements. In one report,
of 355 subjects with PTPS deﬁciency, one-ﬁfth presented with the
mild “peripheral” phenotype.8
PTPS deﬁciency can be diagnosed by ﬁnding HPA as part of
standard newborn screening that is followed by proper evaluation
to look for BH4 deﬁciencies as a potential cause for HPA. Alterna-
tively, PTPS deﬁciency can be diagnosed either in symptomatic
infants presenting with neurological deterioration who were
diagnosed with HPA by NBS but were presumed to have phenyl-
alanine hydroxylase deﬁciency and treated with diet only or in
infants who did not have NBS or in whom the screen was false-
negative. ID, hypotonia, and convulsions are the most common
presenting symptoms in the severe phenotype of PTPS deﬁciency8
(Table 3). Among disorders of BH4 metabolism, PTPS deﬁciency has
the highest risk of prematurity and low birth weights.8 Subjects
with PTPS deﬁciency have signiﬁcantly higher phenylalanine con-
centrations compared with other disorders of BH4 metabolism.8
Mutation spectrum in the PTS gene and geographical distribution
In 1986, 6-pyruvoyltetrahydropterin synthase was puriﬁed from
human liver.15 Thony et al. cloned and expressed the human cDNAs
for the PTPS enzyme, which was subsequently mapped to the
chromosomal region 11q22.3-q23.3.16 PTS gene spans about eight
kilobases and contains six exons.17 In 1994, Thony et al. character-
ized, for the ﬁrst time, three variants in two subjects with PTPS
deﬁciency.18 Since then, several pathogenic variants were identi-
ﬁed, and 141 variants are currently listed in the Database of Gene
Variants Causing BH4 Deﬁciencies and other pediatric neuro-
transmitter disease (PNDdb), distributed across all six exons and
ﬁve introns (http://www.biopku.org/pnddb/home.asp; accessed on
December 10, 2018). No hotspots for mutations are found,19
although some of the reported pathogenic variants are more
common in certain ethnicities. For example, in one study, molecular
analysis of the PTS gene was performed on 176 subjects from East
Asia, including the Han populations in Taiwan, Mainland China, and
Malaysia, as well as the populations of Japan, South Korea, Thailand,
and the Philippines. Five variants (c.155A>G, c.259C>T, c.272A>G,
c.286G>A, and c.84-291A>G) were themost common, with the ﬁrst
two accounting for 15.6% and 37.5%, respectively, of the allele count.
Two variants (c.58T>C and c.243G>A) were dominant in the
Philippines and Okinawa, Japan, respectively, indicating founder
events restricted to these isolated geographic regions.9 From
PNDdb, two variants (c.260C>T and c.407A>T) are commonly re-
ported in Caucasian subjects. In our local cohort, the most common
variant is c.238A>G with an allele count of 33%. Interestingly, all
individuals with this variant belong to the same tribe in Saudi
Arabia, indicating a founder effect, which is a common phenome-
non in Saudi Arabia and Arabs in general.20 The missense variant
c.200C>T is reported in two individuals here, both originating from
North Africa (Egyptian and Sudanese). This variant is also reported
in seven subjects in the PNDdb with different ethnic backgrounds,
including Caucasian, Chinese, and Tamil. One novel variant is
identiﬁed in this report: c.2T>G. Pathogenic variants affecting the
initiation codon (c.1A>G and c.3G>A) have been reported.9,21
Treatment and outcome
There are two main goals of treatment in subjects with PTPS
deﬁciency: ﬁrst is controlling HPA with oral BH4 and second is
restoring neurotransmitter homeostasis by administering biogenic
amine precursors (L-dopa/carbidopa and 5-OH-Trp). The recom-
mended dose range for BH4 is 5 to 10 mg/kg/day, whereas for L-
dopa and 5-OH-Trp, the recommended doses are slightly variable
based on age. For children, the recommend dose is 8 to 15 mg/kg/
day and 6 to 9 mg/kg/day, respectively.8 Replacement therapy for
dopamine is more difﬁcult than replacing serotonin, mainly
because of the short half-life of L-dopa and the associated adverse
advents. In one study, it was shown that administering dopamine
agonist, pramipexole, was associated with a reduction in L-dopa
dosage and in potentiating the effects of L-dopa therapy22; high
doses were associated with impulse control disorders, whereas low
doses were safe and clinically effective.23 Long-term L-dopa therapy
may result in low 5-methyltetrahydrofolate levels in CSF, and
therefore CSF folate should also be monitored and replaced in
deﬁcient subjects through folinic acid administration.24
Besides plasma phenylalanine levels and clinical evaluation,
monitoring the efﬁcacy of therapy in subjects with PTPS deﬁciency
requires regularmeasurements of neurotransmittermetabolites (5-
HIAA and HVA) in CSF. Low CSF5-HIAA and HVA values could be an
indicator for the ongoing developmental impairment.24 In a report
of 36 patients, Jaggi et al. did not ﬁnd clear correlation between CSF
5-HIAA and HVA values and clinical outcome.24 CSF neurotrans-
mitter testing is challenging as it requires invasive procedure and
TABLE 2.
PTS Variants in This Report
DNA Nucleotide Change Protein Amino Acid Change # Homozygous
(Families)
# Heterozygous
(Families)
Total Allele Count
(Families)
Origin
c.2T>G p.? 1 0 2 Saudi
c.155A>G p.N52S 1 0 2 Saudi
c.169_171del p.V57del 4 0 8 Saudi
c.200C>T p.T67M 2 0 4 Egyptian/Sudanese
c.238A>G p.M80V 8 0 16 Saudi
c.342C>G p.I114M 4 0 8 Saudi
c.367C>T p.P123S 3 0 6 Omani
c.400G>A p.E34K 1 0 2 Omani
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TABLE 3.
Summary of Previous Cohorts of Subjects With PTPS Deﬁciency
Dudesek et al., 2001 Liu et al., 2001 Chien et al., 2001 Lee et al., 2006 Wang et al., 2006 Jaggi et al., 2008
Number of subjects 5 5 10 10 31 26
Ethnicity Turkish and German Chinese Taiwanese Chinese Chinese Mixed
Prematurity 2/5 0/5 NA NA NA 4/26
Birth weight (kg) 2.18-3.5
(Mean 2.66, median 2.67)
2.7-3
(Mean and median 2.85)
2.66 ± 1.97 NA
3/10 born SGA
3.1 ± 0.5 1.4-3.3
(Mean 2.6, median 2.8)
Age at diagnosis of PTPS
deﬁciency
18 d-7 yr
(Mean 20 mo, median 3 mo)
10 mo-14 yr
(Mean 43 mo, median 14 mo)
NA (all diagnosed through NBS) 8 mo-20 yr
(Mean 6 yr, median 3.5 yr)
2 mo-47.5 mo
(Mean 8.6 mo, median 5 mo)
1 wk-27 yr
(Mean 9 mo, median 1 mo)
Presentation
Developmental delay/intellectual
disability
1/5 3/5 NA NA 22/26 NA
Tone abnormalities 3/5 4/5 NA NA 19/26 NA
Seizures 1/5 3/5 NA NA 10/26 NA
Movement disorders 4/5 0/5 NA NA 11/26 NA
Initial biochemical proﬁle
Phenylalanine level (mmol/L) 80-1398
(Mean 635, median 541)
236-1210
(Mean 830, median 938)
423-2280
(Mean 1316, median 1367
234-2340
(Mean 1211, median 1137)
181-2054
(Mean 964, median 960)
180-2117
(Mean 841, median 713)
Neopterin mmol/mol cr (1.1-4) 1.6-32.8
(Mean 17.6, median18.7)
NA NA 5.92-5.92
(Mean 21.1, median 18.8)
1.5 -31
(Mean 7, median 4.5)*
2-40.5
(Mean 18, median 17)
Biopterin mmol/mol cr (0.5-3) 0-0.65
(Mean 0.2, median 0.1)
NA NA 0.005-0.5
(Mean 0.18, median 0.16)
0.01-0.81
(Mean 0.2, median 0.14)*
<0.01-0.56
Phenotype Severe 4/5
Mild 1/5
Severe 4/5
Mild 1/5
NA Severe 8/10
Mild 2/10
NA NA
Treatment
BH4 (mg/kg/day) 2.1-6.5
(Mean 3.85, median 3.4)
(4/5 taking)
NA 1.50 ± 0.44
(0.75-2.14)
NA 1.1-3
(Mean 1.9, median 1.8)
3-12
(Mean 6.5, median 6)
L-Dopa (mg/kg/day) 6.9 and 7.1
(2/5 taking)
NA 8.39 ± 3.67
(3.77-14.40)
NA 5.8-12.5
(Mean 9.3, median 8.8)
4-18
(Mean 9, median 9.5):
(22/26 taking)
5-OH-Trp (mg/kg/day) 4.2 and 5.6
(2/5 taking)
NA 2.13 ± 1.76
(0.00-5.32)
NA 3.6-6
(Mean 4.7, median 4.3)
4-10
(Mean 6.8, median 7)
(23/26 taking)
Developmental delay/ID on
last follow-up
(severity variable)
3/5 NA 10/10
Mean IQ 76 ± 14 (56-98)
10/10
IQ (<20-80)
7/26 had IQ less than 70
(57-115, Mean and
median 80)
10/26
Liu et al., 2008 Leuzzi et al., 2009 Opladen et al., 2012 Ye et al., 2013 Fernandez-Lainez et al., 2018 Souza et al., 2018
Number of subjects 12 19 335 240 5 4
Ethnicity Taiwanese Italian Mixed Chinese Mexican Brazilian
Prematurity 1/12 1/19 Gestational age 28-37 (Mean 35) NA 2/5
Gestational age 35-38
(Mean 37, median 38)
NA
Birth weight (kg) 2-3.3
(Mean 2.6, median 2.65)
1.02 -3.5
(Mean 2.7, median 2.8)
<1.5 (3.6%)
1.5-2(8.9%)
2-2.5(25.8%)
2.5-3 (33.3%)
- 3-3.4(20.4%)
>3.5 (8%)
Mean (S.D.) birth weight was
3.1 (0.5) kgz
1.8-3.3
(Mean 2.47, median 2.55)
3/5 born SGA
NA
Age at diagnosis of PTPS
deﬁciency
Neonatal period
Mean age of diagnosis
20.0 (6.3) d
8 d-32 yr
(Mean 25 mo, median
1 mo)
Mean 1.8 yr 0.5-156
(Mean 11.5, median 3)
1-38 mo (Mean 17 mo,
median 5 mo)
5-96 mo
(Mean 27 and median 4.5)
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Presentation
Developmental
delay/intellectual disability
NA 8/19 Neonates 30% y
Infants 45%y
Children 52%y
NAx 5/5 4/4
Tone abnormalities NA 7/19 Neonates 40% y
Infants 62%y
Children 40%y
NAx 4/5 4/4
Seizures NA 2/19 Neonates 10%y
Infants 50%y
Children 40%y
NAx 5/5 1/4
Movement disorders NA 3/19 Neonates 10%y
Infants 18%y
Children 25%y
NAx 5/5 0/4
Initial biochemical Proﬁle
Phenylalanine level (mmol/L) 527-3426
(Mean 1963, median 2002)
151-2120
(Mean 1025, median 1051)
Severe phenotype 829 (121e2251)
Mild phenotype 1111 (41e3805)
242-2724
(Mean 1035, median 974)
419-1027
(Mean 751, median 779)
538-2582
(Mean 1552, median 1544)
Neopterin mmol/mol cr (1.1-4) NA 3.5-44.1
(Mean 17, median 13)
Severe phenotype 21 (1.6e134)
Mild phenotype
17.1 (1.9e78)
0.08-70.7
(Mean 12.6, median 9.4)
4.69-11.88
(Mean 6.9, median 6.5)
NA
Biopterin mmol/mol cr (0.5-3) NA <0.01-0.55 Severe phenotype 0.2 (0e7.8)
Mild Phenotype
0.3 (0e1.6)
0-2.69
(Mean 0.24, median 0.13)
0-0.07
(Mean and median 0.04)
NA
Phenotype NA Severe 13
Mild 6
84.9 % severe
15.1 % mild
NA NA NA
Treatment
BH4 (mg/kg/day) 2-4 2-21 Neonates 5.6 (1.8e15)
Infants 5.3 (0.5e16)
Children 5.5 (0.4e20)
NA NA NA
L-Dopa (mg/kg/day) 10-15.5
(Mean 12, median 11.25
1-10 Neonates 5.9 (1e12)
Infants 7.2 (0.1e44)
Children 8.6 (0.3e49)
NA NA NA
5-OH-Trp (mg/kg/day) 1-5.8
(Mean 3.9, median 4)
1-8 Neo 4.5 (0.6e10)
Infants 5.4 (0.5e42)
Children 6.1 (0.5e37)
NA NA NA
Developmental delay/ID on last
follow-up (severity variable)
IQ 86-111
(Mean 97, median 95)
8/19 NA IQ 36-11 (Mean 79, median 80);
available for 31 subjects
3/5 NA
Abbreviations:
Cr ¼ Creatinine
DHPR ¼ Dihydropteridine reductase
GTPCH ¼ GTP cyclohydrolase I
ID ¼ Intellectual disability
IQ ¼ Intelligence quotient
NA ¼ Not available or not applicable
NBS ¼ Newborn screening
SGA ¼ Small for gestational age
* nmol/l
y Out of subjects with severe phenotype
z Calculations included six subjects with DHPR deﬁciency and four subjects with GTPCH deﬁciency (total 250)
x 73.6 % of patients presented with typical symptoms of BH4 deﬁciency (including hypotonia, apathy, drowsiness, low response, drooling, and retardation of motor development), 70.4 % with systemic symptoms of HPA
(including yellow hair, white skin, characteristic body odor, convulsions, mental retardation, occasional tremors, and microcephaly), and 4.0 % with other symptoms (including eczema and vomiting).
M
.A
lm
annai
et
al./
Pediatric
N
eurology
96
(2019)
40
e
47
45
specialized laboratory facilities to analyze the samples, which are
not readily available. This was a challenge that we faced with our
local subjects. Alternatively, plasma prolactin levels, which
correlate inversely with hypothalamic dopamine levels, could be
used,25 as dopamine originating from the hypothalamic tuber-
oinfundibular tract is the major physiological inhibitor for
prolactin.26 Ogawa et al. described an individual with more
signiﬁcant correlation of L-dopa dose with serum prolactin levels
than CSF HVA levels.27 Similarly, in another study, monitoring
serum prolactin was used successfully for optimizing the dosage
of L-dopa.28 However, prolactin levels do not reﬂect serotonin
homeostasis and could also ﬂuctuate due to external factors such
as exercise and stress.29 Prolactin secretion has marked diurnal
variations, with lowest levels found shortly after awakening.
Therefore, this time is chosen for the basal evaluation of prolactin
secretion.26
Developmental outcome is worse in those who are treated late
(i.e., greater than two months). In a report of 10 subjects from
Taiwan, the average IQ score was 76 ± 14, and it was inversely
correlated to the age of starting medication.11 A similar observa-
tion was made in another report.30 Wang et al. showed that sub-
jects who were diagnosed by neonatal screening had much higher
development quotient or IQ than those who were diagnosed
symptomatically (88 versus 62, respectively).30 Leuzzi et al.
showed that only two of eight subjects with late (greater than
two months) treatment had normal mental development,
whereas all the others were neurologically impaired.31 In a Chi-
nese study, the median age at which treatment was started was
signiﬁcantly (P value 0.02) less in subjects with an IQ above 70
than in those with an IQ below 70.32 Tanaka et al. showed that
individuals with PTPS deﬁciency who were started on treatment
after age 2.5 years performed poorly on tests of executive func-
tioning, and they hypothesized that there is a critical level during
which adequate neurotransmitter levels, especially dopamine, is
required for the stable development of executive functioning.33
Although early treatment is clearly associated with better out-
comes, one report showed that early-treated subjects with PTPS
deﬁciency may not maintain movement rhythm as well as normal
subjects, even with external cues.34
Conclusion and future directions
PTPS deﬁciency is relatively common in the Arab population
and should be considered in individuals with hyper-
phenylalaninemia. It is apparent from several studies that early
treatment is associated with better outcome, so early diagnosis
cannot be stressed enough. Although NBS is becoming widely
available in different areas of the world, still there are missed
cases owing to failure to recognize BH4 deﬁciencies, including
PTPS deﬁciency, as a potential cause for HPA. Therefore, adding
metabolites speciﬁc for BH4 deﬁciencies could help in early
diagnosis. In fact, measuring neopterin and biopterin from direct
blood spot for routine diagnosis of BH4 deﬁciencies proved to be
useful in one study.35 With wide availability of next-generation
sequencing methods and reduced cost, these methods could
also be utilized in newborn screening.36
In the near future, more therapeutic options could become
available for PTPS deﬁciency. It was shown very early that gene
delivery into primary patients' ﬁbroblasts restored BH4 produc-
tion.37 Antisense oligonucleotides were used successfully to induce
pseudoexon exclusion in ﬁbroblasts of patients with splicing vari-
ants and restored PTPS enzyme activity and pterin proﬁle.38 Finally,
given the relatively common prevalence of PTPS deﬁciency in our
area, we need a regional collaborative effort to establish a
specialized laboratory for BH4 deﬁciencies.
Acknowledgement
We would like to thank the participating patients and families.
Supplementary data
Supplementary data to this article can be found at https://doi.
org/10.1016/j.pediatrneurol.2019.02.008.
References
1. Hardelid P, Cortina-Borja M, Munro A, et al. The birth prevalence of PKU in
populations of European, South Asian and sub-Saharan African ancestry living
in South East England. Ann Hum Genet. 2008;72:65e71.
2. Guthrie R, Susi A. A Simple phenylalanine method for detecting phenylketon-
uria in large populations of newborn infants. Pediatrics. 1963;32:338e343.
3. Kaufman S. The structure of the phenylalanine-hydroxylation cofactor. Proc
Natl Acad Sci U S A. 1963;50:1085e1093.
4. Danks DM, Bartholome K, Clayton BE, et al. Malignant hyperphenylalaninaemia–
current status (June 1977). J Inherit Metab Dis. 1978;1:49e53.
5. Danks DM, Cotton RG, Schlesinger P. Diagnosis of malignant hyper-
phenylalaninaemia. Arch Dis Child. 1979;54:329e330.
6. Th€ony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration
and functions. Biochem J. 2000;347:1e16.
7. Blau N, Bonafe L, Th€ony B. Tetrahydrobiopterin deﬁciencies without hyper-
phenylalaninemia: diagnosis and genetics of dopa-responsive dystonia and
sepiapterin reductase deﬁciency. Mol Genet Metab. 2001;74:172e185.
8. Opladen T, Hoffmann GF, Blau N. An international survey of patients with
tetrahydrobiopterin deﬁciencies presenting with hyperphenylalaninaemia.
J Inherit Metab Dis. 2012;35:963e973.
9. Chiu Y-H, Chang Y-C, Chang Y-H, et al. Mutation spectrum of and founder ef-
fects affecting the PTS gene in East Asian populations. J Hum Genet. 2012;57:
145e152.
10. Liu TT, Chiang SH, Wu SJ, Hsiao KJ. Tetrahydrobiopterin-deﬁcient hyper-
phenylalaninemia in the Chinese. Clin Chim Acta Int J Clin Chem. 2001;313:
157e169.
11. Chien YH, Chiang SC, Huang A, et al. Treatment and outcome of Taiwanese
patients with 6-pyruvoyltetrahydropterin synthase gene mutations. J Inherit
Metab Dis. 2001;24:815e823.
12. Khatami S, Dehnabeh SR, Zeinali S, et al. Four years of diagnostic challenges
with tetrahydrobiopterin deﬁciencies in Iranian patients. JIMD Rep. 2017;32:
7e14.
13. Jardim LB, Giugliani R, Coelho JC, Dutra-Filho CS, Blau N. Possible high fre-
quency of tetrahydrobiopterin deﬁciency in south Brazil. J Inherit Metab Dis.
1994;17:223e229.
14. Blau N. Genetics of phenylketonuria: then and now. Hum Mutat. 2016;37:
508e515.
15. Takikawa S, Curtius HC, Redweik U, Ghisla S. Puriﬁcation of 6-pyruvoyl-tet-
rahydropterin synthase from human liver. Biochem Biophys Res Commun.
1986;134:646e651.
16. Th€ony B, Heizmann CW, Mattei MG. Chromosomal location of two human
genes encoding tetrahydrobiopterin-metabolizing enzymes: 6-pyruvoyl-tet-
rahydropterin synthase maps to 11q22.3-q23.3, and pterin-4 alpha-carbinol-
amine dehydratase maps to 10q22. Genomics. 1994;19:365e368.
17. Kluge C, Brecevic L, Heizmann CW, Blau N, Th€ony B. Chromosomal localization,
genomic structure and characterization of the human gene and a retro-
pseudogene for 6-pyruvoyltetrahydropterin synthase. Eur J Biochem.
1996;240:477e484.
18. Th€ony B, Leimbacher W, Blau N, Harvie A, Heizmann CW. Hyper-
phenylalaninemia due to defects in tetrahydrobiopterin metabolism: molecu-
lar characterization of mutations in 6-pyruvoyl-tetrahydropterin synthase. Am
J Hum Genet. 1994;54:782e792.
19. Th€ony B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase
I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-
4a-dehydratase, and dihydropteridine reductase. Hum Mutat. 2006;27:
870e878.
20. Al-Owain M, Al-Zaidan H, Al-Hassnan Z. Map of autosomal recessive genetic
disorders in Saudi Arabia: concepts and future directions. Am J Med Genet A.
2012;158A:2629e2640.
21. Wang R, Shen N, Ye J, et al. Mutation spectrum of hyperphenylalaninemia
candidate genes and the genotype-phenotype correlation in the Chinese
population. Clin Chim Acta Int J Clin Chem. 2018;481:132e138.
22. Porta F, Mussa A, Concolino D, Spada M, Ponzone A. Dopamine agonists in 6-
pyruvoyl tetrahydropterin synthase deﬁciency. Neurology. 2009;73:633e637.
23. Porta F, Ponzone A, Spada M. Long-term safety and effectiveness of prami-
pexole in tetrahydrobiopterin deﬁciency. Eur J Paediatr Neurol. 2016;20:
839e842.
24. J€aggi L, Zurﬂüh MR, Schuler A, et al. Outcome and long-term follow-up of 36
patients with tetrahydrobiopterin deﬁciency. Mol Genet Metab. 2008;93:
295e305.
M. Almannai et al. / Pediatric Neurology 96 (2019) 40e4746
25. Dudesek A, R€oschinger W, Muntau AC, et al. Molecular analysis and long-term
follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin
synthase deﬁciency. Eur J Pediatr. 2001;160:267e276.
26. Spada M, Ferraris S, Ferrero GB, et al. Monitoring treatment in tetrahy-
drobiopterin deﬁciency by serum prolactin. J Inherit Metab Dis. 1996;19:
231e233.
27. Ogawa A, Kanazawa M, Takayanagi M, Kitani Y, Shintaku H, Kohno Y. A case of
6-pyruvoyl-tetrahydropterin synthase deﬁciency demonstrates a more signif-
icant correlation of L-Dopa dosage with serum prolactin levels than CSF
homovanillic acid levels. Brain Dev. 2008;30:82e85.
28. Vatanavicharn N, Kuptanon C, Liammongkolkul S, et al. Novel mutation
affecting the pterin-binding site of PTS gene and review of PTS mutations in
Thai patients with 6-pyruvoyltetrahydropterin synthase deﬁciency. J Inherit
Metab Dis. 2009;32(Suppl 1):S279eS282.
29. Lennartsson A-K, Jonsdottir IH. Prolactin in response to acute psychosocial
stress in healthy men and women. Psychoneuroendocrinology. 2011;36:
1530e1539.
30. Wang L, Yu W-M, He C, et al. Long-term outcome and neuroradiological
ﬁndings of 31 patients with 6-pyruvoyltetrahydropterin synthase deﬁciency.
J Inherit Metab Dis. 2006;29:127e134.
31. Leuzzi V, Carducci CA, Carducci CL, et al. Phenotypic variability, neurological
outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase
deﬁciency. Clin Genet. 2010;77:249e257.
32. Ye J, Yang Y, Yu W, et al. Demographics, diagnosis and treatment of 256 pa-
tients with tetrahydrobiopterin deﬁciency in mainland China: results of a
retrospective, multicentre study. J Inherit Metab Dis. 2013;36:893e901.
33. Tanaka Y, Kato M, Muramatsu T, et al. Early initiation of L-dopa therapy enables
stable development of executive function in tetrahydrobiopterin (BH4) deﬁ-
ciency. Dev Med Child Neurol. 2007;49:372e376.
34. Kao C-D, Niu D-M, Chen J-T, et al. Subtle brain dysfunction in treated 6-
pyruvoyl-tetrahydropterin synthase deﬁciency: relationship to motor tasks
and neurophysiological tests. Brain Dev. 2004;26:93e98.
35. Opladen T, Abu Seda B, Rassi A, Th€ony B, Hoffmann GF, Blau N. Diagnosis of tet-
rahydrobiopterin deﬁciency using ﬁlter paper blood spots: further development
of the method and 5 years experience. J Inherit Metab Dis. 2011;34:819e826.
36. Chaiyasap P, Ittiwut C, Srichomthong C, Sangsin A, Suphapeetiporn K,
Shotelersuk V. Massive parallel sequencing as a new diagnostic approach for
phenylketonuria and tetrahydrobiopterin-deﬁciency in Thailand. BMC Med
Genet. 2017;18:102.
37. Th€ony B, Leimbacher W, Stuhlmann H, Heizmann CW, Blau N. Retrovirus-
mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase corrects tet-
rahydrobiopterin deﬁciency in ﬁbroblasts from hyperphenylalaninemic pa-
tients. Hum Gene Ther. 1996;7:1587e1593.
38. Brasil S, Viecelli HM, Meili D, et al. Pseudoexon exclusion by antisense therapy
in 6-pyruvoyl-tetrahydropterin synthase deﬁciency. Hum Mutat. 2011;32:
1019e1027.
M. Almannai et al. / Pediatric Neurology 96 (2019) 40e47 47
